Etanercept: a new era in the treatment of psoriatic arthritis.

Abstract

Psoriatic arthritis (PsA) can exact a devastating physical and emotional toll from its sufferers. For decades, patients have been understandably dismayed by the shortcomings of the therapeutic approaches that have been available. Now, equipped with a greater understanding of the role of cytokines such as tumor necrosis factor in the origins of PsA, researchers have been able to develop cytokine inhibitors aimed precisely at the mechanisms of cutaneous and articular inflammation. When used in combination with physical rehabilitation, pharmacologic therapy can slow or arrest the progression of PsA and profoundly improve the quality of life of PsA patients.

• Authors: Philip J Mease
• Journal: The American journal of managed care (Am J Manag Care) Vol. 8 Issue 6 Suppl Pg. S181-93 (Apr 2002) ISSN: 1088-0224 [Print] United States
• PMID: 11990863 (Publication Type: Journal Article, Review)

Chemical References

• Antirheumatic Agents
• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Etanercept

Topics

• Antirheumatic Agents (therapeutic use)
• Arthritis, Psoriatic (drug therapy)
• Clinical Trials as Topic
• Etanercept
• Humans
• Immunoglobulin G (therapeutic use)
• Receptors, Tumor Necrosis Factor (therapeutic use)